Assuntos
Unha-de-Gato , Inibidores da Protease de HIV , Interações Ervas-Drogas , Preparações de Plantas , Sulfato de Atazanavir , Unha-de-Gato/efeitos adversos , Feminino , Inibidores da Protease de HIV/administração & dosagem , Inibidores da Protease de HIV/sangue , Inibidores da Protease de HIV/farmacocinética , Inibidores da Protease de HIV/uso terapêutico , Humanos , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Oligopeptídeos/administração & dosagem , Oligopeptídeos/sangue , Oligopeptídeos/farmacocinética , Oligopeptídeos/uso terapêutico , Preparações de Plantas/administração & dosagem , Preparações de Plantas/efeitos adversos , Piridinas/administração & dosagem , Piridinas/sangue , Piridinas/farmacocinética , Piridinas/uso terapêutico , Ritonavir/administração & dosagem , Ritonavir/sangue , Ritonavir/farmacocinética , Ritonavir/uso terapêutico , Saquinavir/administração & dosagem , Saquinavir/sangue , Saquinavir/farmacocinética , Saquinavir/uso terapêuticoRESUMO
No disponible
No disponible
Assuntos
Feminino , Humanos , Masculino , Testes Laboratoriais/análise , Testes Laboratoriais/métodos , Hepatite C Crônica/metabolismo , Hepatite C Crônica/transmissão , Soro/citologia , Soro/metabolismo , Testes Laboratoriais/efeitos adversos , Testes Laboratoriais/classificação , Hepatite C Crônica/sangue , Hepatite C Crônica/virologia , Biomarcadores/sangue , Biomarcadores/química , Genótipo , Soro/química , Soro/virologiaRESUMO
OBJECTIVE: The efficacy of recombinant alfa-2b interferon therapy in C-virus (HCV) and G-virus (HGV) in children with chronic hepatitis C was evaluated. PATIENTS AND METHODS: Fifteen patients, between 6 and 16 years of age and positive for HCV of which four were also infected with HGV, were treated with interferon (3 M three times a week for 6 months). The responders were treated for 12 months. HCV RNA, antibodies to HCV, HVC viral genome (expressed as 1000 copy equivalents of HCV genome = 1 keq), HGV RNA (RT/PCR, 5'NCR-NS5), and E2-HGV antibodies were determined before treatment and at 3 and 6 months in all patients and at 12-24 months in the responders. RESULTS: Four HCV patients (27%) with low viral load (mean 36 keg/ml) showed good results after interferon treatment and two of them (13%) with genotypes 1b and 3 according to Simmond's classification showed a maintained response. The four HGV children also showed the same good results and the RNA was negative without sero-conversion to anti-E2 after 12 months of interferon treatment. In the post-interferon treatment period, the HGV RNA appeared again in the serum in 3 of the 4 children. In the child with a maintained response, serum conversion to anti-E2 was not detected. CONCLUSIONS: 1) The current results, with only 13% of the patients reaching a sustained response, question the systematic treatment of all children affected with hepatitis C virus. Since the cost-benefit ratio is not yielding the expected results, such therapy may be reserved for patients with genotype other than 1b and a low level of viral genome. 2) HGV is sensitive to treatment with interferon, although the infection frequently appears again once the treatment is over.
